Gilead Sciences, Inc. (NASDAQ: GILD) reported total revenue of $6.6 billion for the second quarter of 2023, which was up 5% year-over-year.

Net income attributable to Gilead was $1 billion, or $0.83 per share, compared to $1.1 billion, or $0.91 per share, last year. Adjusted EPS was $1.34.
For the full year of 2023, GAAP EPS is expected to be $4.50-4.85 while adjusted EPS is estimated to be $6.45-6.80.
Prior performance

Most Popular
Key metrics from Biogen’s (BIIB) Q4 2024 earnings results
Biogen Inc. (NASDAQ: BIIB) reported its fourth quarter 2024 earnings results today. Total revenue increased 3% year-over-year to $2.5 billion. Net income attributable to Biogen Inc. was $266.8 million,
Important takeaways from Coca-Cola’s (KO) Q4 2024 earnings
The Coca-Cola Company (NYSE: KO) has wrapped up fiscal 2024 on an upbeat note, reporting stronger-than-expected results for the final quarter of the year. Encouraged by the growth in sales
Walt Disney (DIS): A look at the performance of the streaming business in 1Q25
Shares of The Walt Disney Company (NYSE: DIS) dropped 1% on Tuesday. The stock has gained 6% over the past three months. The company delivered top and bottom line growth